Related Experiment Videos
Some clinical problems in patients undergoing thrombolytic therapy
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
|February 21, 1976
Summary
Streptokinase therapy is safe and effective for early iliofemoral venous thrombosis. This treatment involves 72 hours of streptokinase followed by 24 hours of heparin.
Area of Science:
- Vascular Surgery
- Thrombosis Treatment
- Pharmacological Interventions
Background:
- Iliofemoral venous thrombosis poses significant risks.
- Early intervention is crucial for favorable outcomes.
- Streptokinase is a thrombolytic agent with potential therapeutic applications.
Purpose of the Study:
- To evaluate the safety and efficacy of streptokinase in treating early iliofemoral venous thrombosis.
- To assess clinical outcomes and complications associated with streptokinase therapy.
Main Methods:
- A cohort of 25 patients with iliofemoral venous thrombosis received streptokinase for 72 hours.
- Patients subsequently received heparin for 24 hours post-streptokinase treatment.
- Clinical data, complications, and treatment results were systematically recorded and analyzed.
Main Results:
- Streptokinase demonstrated a safe and effective therapeutic profile in the studied patient group.
- The treatment regimen was associated with manageable clinical problems and complications.
- Positive outcomes were observed in patients with early-stage iliofemoral venous thrombosis.
Conclusions:
- Streptokinase is a viable and effective treatment option for early iliofemoral venous thrombosis.
- The study supports the use of streptokinase within its limitations for this condition.
- Further research may explore optimal treatment durations and patient selection criteria.